Fariba Sadeghi Fazel1, Mahnaz Haddadi2, Alireza Khoshnevisan3, Samad Muhammadnejad4, Ahad Muhammadnejad2, Zohreh Mazaheri5, Motahareh Arjomandnejad6, Reza Shirkoohi2, Mohammad-Ali Oghabian4, Narjes Sherkat-Khameneh4, Saeid Amanpour2, Monireh Kazemimanesh7. 1. Health Management Department, Quality Assurance Deputy, Razi Vaccine & Serum Research Institute, Karaj, Iran. 2. Cancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran. 3. Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 4. Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran. 5. Anatomy Department, School of Medicine, Tarbiat Modares University, Tehran, Iran. 6. Omid Institute for Advance Biomodels, Incubation Center for Medical Devices, Tehran University of Medical Sciences, Tehran, Iran. 7. Virology Department, Pasteur Institute of Iran, Tehran, Iran.
Abstract
OBJECTIVES: P In vitro chemosensitivity and resistance assays (CSRAs) are a promising tool for personalized treatment of glioblastoma multiform (GBM). These assays require a minimum of 1 to 2 g of tumor specimen for testing, but this amount is not always accessible. We aimed to assess the feasibility and validity of utilizing stereotactic biopsies of GBM in CSRAs. MATERIALS AND METHODS: Single cell suspension was prepared from 1 g weight explants of the established xenograft tumor of GBM. Also, primary culture was carried out on 35 mg weight specimens, as a surrogate for stereotactic biopsies. Then, chemoresponse profile of cells obtained by direct cell disaggregation and primary culture was determined using temozolomide and carmustine by clonogenic assay. RESULTS: There was no statistically significant difference in the cytotoxicity of temozolomide and carmustine between cells obtained from both methods. CONCLUSION: This work supports the feasibility of using stereotactic biopsies of GBM in CSRAs.
OBJECTIVES: P In vitro chemosensitivity and resistance assays (CSRAs) are a promising tool for personalized treatment of glioblastoma multiform (GBM). These assays require a minimum of 1 to 2 g of tumor specimen for testing, but this amount is not always accessible. We aimed to assess the feasibility and validity of utilizing stereotactic biopsies of GBM in CSRAs. MATERIALS AND METHODS: Single cell suspension was prepared from 1 g weight explants of the established xenograft tumor of GBM. Also, primary culture was carried out on 35 mg weight specimens, as a surrogate for stereotactic biopsies. Then, chemoresponse profile of cells obtained by direct cell disaggregation and primary culture was determined using temozolomide and carmustine by clonogenic assay. RESULTS: There was no statistically significant difference in the cytotoxicity of temozolomide and carmustine between cells obtained from both methods. CONCLUSION: This work supports the feasibility of using stereotactic biopsies of GBM in CSRAs.
Entities:
Keywords:
Glioblastomamultiform; In vitro chemosensitivity and resistance assay; Personalized medicine; Primary explant technique; Stereotactic biopsy
Authors: R J Jackson; G N Fuller; D Abi-Said; F F Lang; Z L Gokaslan; W M Shi; D M Wildrick; R Sawaya Journal: Neuro Oncol Date: 2001-07 Impact factor: 12.300
Authors: M G Castro; R Cowen; I K Williamson; A David; M J Jimenez-Dalmaroni; X Yuan; A Bigliari; J C Williams; J Hu; P R Lowenstein Journal: Pharmacol Ther Date: 2003-04 Impact factor: 12.310
Authors: Robert L Ochs; Jeffrey Fensterer; N Paul Ohori; Alan Wells; Michael Gabrin; Lisa D George; Paul Kornblith Journal: In Vitro Cell Dev Biol Anim Date: 2003 Jan-Feb Impact factor: 2.416
Authors: Zhibao Mi; Frankie A Holmes; Beth Hellerstedt; John Pippen; Rufus Collea; Amanda Backner; Jason E Bush; Holly H Gallion; Alan Wells; Joyce A O'Shaughnessy Journal: Anticancer Res Date: 2008 May-Jun Impact factor: 2.480